Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides
Shengle Zhang(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Kenneth O. Lloyd(Institute for Protein Innovation), Carlos Cordon‐Cardo(Icahn School of Medicine at Mount Sinai), Sucharita Adluri(Memorial Sloan Kettering Cancer Center), Wm. Bradley Hamilton(Memorial Sloan Kettering Cancer Center), Helen S. Zhang(Memorial Sloan Kettering Cancer Center), Victor E. Reuter(Memorial Sloan Kettering Cancer Center)
International Journal of Cancer
September 26, 1997
Cited by 278
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
|Nature Medicine|2019|2.6k
Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis
|Cell|1996|797
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
|JAMA Oncology|2018|661
Molecular Cloning of the CA125 Ovarian Cancer Antigen
|Journal of Biological Chemistry|2001|656